XOMA Royalty Corporation Depositary Shs Repr 1/1000th 8.375% Cum Conv Perp Red Pfd Rg Shs Series B XOMAO 深 滬
已收盤 05-08 16:00:00 美东时间
25.295
+0.055
+0.22%
華盛通- 最 高25.295
- 今 開25.22
- 成交量 4857股
- 最 低 25.22
- 昨 收 25.24
- 總市值 4453.18万
- 52周最高 26.40
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 22.9562
- 委 比 92.04%
- 總股本 176.05万
- 歷史最高 26.40
- 量 比 0.42
- 振 幅 0.30%
- 歷史最低 13.5463
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
05-09 05:57
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
04-27 23:24
Suja Life launches IPO roadshow, targets $21–$24 per share
Suja Life (SUJA) on Monday said it has begun the roadshow for its initial public offering of 8,888,889 Class A shares, with a price range of $21 to $24 per share. Of the total shares, 8,688,170 are be...
04-27 19:40
Ligand to buy XOMA Royalty for $39/share
Ligand Pharmaceuticals (LGND) has agreed to acquire XOMA Royalty (XOMA) for $39.00 per share of common stock in cash, for a total equity value of approximately $739M. The transaction has been unanimou...
04-27 19:32
Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), both biotechnology royalty aggregators, today announced that the companies have entered into a definitive
04-27 19:06
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals to acquire XOMA Royalty for $39 per share, totaling $739 million. The deal adds over 120 assets, including 7 commercial products and nearly doubles Ligand's Phase 2 and 3 pipeline. Ligand expects the transaction to be immediately accretive to EPS, raising 2026 adjusted EPS guidance to $8.50-$9.50 and adding $1.50 per share in 2027. The acquisition is expected to close in Q3 2026, subject to regulatory approvals and stockhol...
04-27 11:00
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology, Inc. reported updates on its lead candidate MICVO, including completion of target enrollment in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the first quarter of 2026. The company also announced updated data expected in mid-2026, which will include patients treated with modified weight-based dosing. Additionally, Pyxis Oncology shared financial results for 2025, includin...
03-23 11:00
XOMA Royalty Corporation (XOMA) Gets a Buy from H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on XOMA Royalt...
03-20 18:36
HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $97 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:XOMA) with a Buy and maintains $97 price target.
03-20 18:30
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Corporation announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary shares will receive $0.52344 per share. Payments are scheduled for April 15, 2026, to holders of record as of April 2, 2026. XOMA Royalty specializes in acquiring future economic rights from biotech therapies, providing non-dilutive funding to sellers and potential ...
03-18 20:30
